[Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
These clinical trials show the efficiency of therapy with angiotensin-converting enzyme (ACE) inhibitors in essential hypertension (EH), chronic heart failure and coronary heart disease (CHD). The SMILE studies have indicated positive results of the early administration (<24 hours) of zofenopril in patients with acute myocardial infarction (AMI). These results have been confirmed in high-risk patients, including those with hypertension and diabetes mellitus, which enables zofenopril to be recommended for clinical use in patients with EH and CHD. Zofenopril has a better safety profile than other agents.